ArticleScientific reports2025
The new bilastine eye drop formulation protects against conjunctival dehydration and promotes corneal wound healing in a comparative in vitro study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Bilastine is a non-sedating, highly selective H1-antihistamine with proven efficacy and safety in treating allergic rhinoconjunctivitis and urticaria in adults and children. Allergic conjunctivitis, a common ocular condition, negatively impacts quality of life. Topical eye drops are the standard treatment, though ocular bioavailability is often low. Incorporating biopolymers such as hyaluronic acid (HA) into topical formulations enhances adhesive properties, prolongs retention on the ocular surface, and ultimately improves drug bioavailability. This study evaluated the new multidose preservative-free bilastine 0.6% solution with sodium HA against eight commercially available antiallergic eye drops. Using an ex vivo bovine cornea model, bilastine 0.6% demonstrated the highest bioadhesion strength (0.025 mJ), indicating superior retention on the ocular surface. It also showed strong protective effects against in vitro dehydration, mainly due to the presence of HA, and did not exhibit cytotoxicity in human primary conjunctival cells. In wound healing assays, preservative-free ketotifen 0.025%, bilastine 0.6%, and azelastine 0.05% promoted corneal wound repair at 72 h, outperforming preserved formulations. Overall, preservative-free bilastine 0.6% with HA enhances corneal hydration, retention, and re-epithelialization in vitro, suggesting potential benefits for the management of allergic conjunctivitis and offering promising advancements in treating this widespread condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.